Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation -- Company Announces Four-Day Subsequent Offer Period for Remaining Shareholders -- Genzyme Becomes a Subsidiary of...
Standard & Poor's Announces Change to U.S. Index PR Newswire NEW YORK, March 29, 2011 NEW YORK, March 29, 2011 /PRNewswire/ -- BlackRock Inc. (NYSE: BLK) will replace Genzyme Corp. (NASD: GENZ...
Genzyme Corporation (NASDAQ: GENZ) announced today that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer...
Genzyme Corporation (Nasdaq: GENZ) today announced that it has completed the sale of its pharmaceutical intermediates business to International Chemical Investors Group...
Genzyme Corporation (NASDAQ: GENZ) today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL...
Genzyme Corporation (NASDAQ: GENZ) today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for...
Genzyme Corp. (NASDAQ: GENZ) today reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase...
Video Available: Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its...
Sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right -- Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its footprint in...
Zacks Analyst Blog Highlights: Laboratory Corporation of America Holdings, Genzyme, Quest Diagnostics, Penn Virginia Resource Partners L.P. and Cloud Peak Energy PR Newswire CHICAGO, Feb. 11...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
